/Investor DB

Biotechnology Value Fund — 2021 Investments

6 investments dated 2021 · listed companies and verified rows first · show all

Alpha-9 Theranostics Inc.alpha9tx.cominApr 2021

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.

BiotechLongevityMedical DevicesBoston, US

Co-investorsFrazier Life SciencesWUTIF CapitalAscenta CapitalLightspeed Venture PartnersLongitude CapitalNextech Invest+1 more

Alpine Immune Sciencesalpineimmunesciences.cominSep 2021 · $91M

BiotechSeattle, US

Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)

Co-investorsDecheng CapitalFrazier Life SciencesOrbiMed

Exo Therapeuticsexo-therapeutics.comin𝕏Oct 2021 · $78M

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian

Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalCasdin Capital+1 more

Nimbusnimbus.energyJul 2021 · $105M

Nimbus Engineering is a hardware company and online retailer developing energy transfer technology, including its patented Power Relay, a portable power outlet for home, office, and outdoor use.

CleantechDeep TechEnergyHardwareSan Francisco, US

Michael Gorman(Founder)in

Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesCommodore CapitalGV (Google Ventures)+2 more

Nimbusnimbusweb.mein𝕏Jul 2021 · $105M

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyAtlas VentureBain Capital Life SciencesCommodore Capital+3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Shoreline Biosciences

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.